• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Health payers–including Medicare and Point32Health–to question Aduhelm pricing and its “reasonable and necessary” use

June 24, 2021 by SharpBrains

State’s Sec­ond-Largest Health Insur­er Slams Bio­gen For Cost­ly Alzheimer’s Drug (The Boston Globe):

The state’s sec­ond-biggest health insur­er is threat­en­ing to lim­it or not cov­er Biogen’s new Alzheimer’s drug, accus­ing the Cam­bridge biotech of putting “exces­sive cor­po­rate prof­its” ahead of patients by charg­ing $56,000 a year for the con­tro­ver­sial treat­ment. Michael Sher­man, chief med­ical offi­cer for Point32Health, the insur­ance com­pa­ny formed by the recent merg­er of Tufts Health Plan and Har­vard Pil­grim Health Care, said Bio­gen should cut the cost of the drug called Aduhelm by a fac­tor of rough­ly 10, to $5,400, giv­en the medicine’s ques­tion­able ben­e­fits and poten­tial risks.

Sen­a­tors Call On Con­gress To Exam­ine Expen­sive New Alzheimer’s Drug (STAT):

Sens. Eliz­a­beth War­ren (D‑Mass.) and Bill Cas­sidy (R‑La.) want Con­gress to take a deep­er look at how Biogen’s con­tro­ver­sial and pricey new Alzheimer’s drug, Aduhelm, will affect the Medicare pro­gram, they wrote in a let­ter Wednes­day. The bipar­ti­san duo is press­ing the Sen­ate Finance Com­mit­tee to take on “the vex­ing new ques­tions and chal­lenges that approval rais­es for the Medicare pro­gram and oth­er health pro­grams” the pan­el over­sees, they wrote.

The Letter from Sens. Elizabeth Warren (D‑Mass.) and Bill Cassidy (R‑La.):

Cas­sidy, War­ren Call for Hear­ing on New Alzheimer’s Dis­ease Drug Aduhelm (press release):

… Under the broad label that FDA approved, the drug is avail­able to all Alzheimer’s patients, and the agency did not place lim­its on treat­ment dura­tion sug­gest­ing that patients could remain on the drug indef­i­nite­ly. We are trou­bled by reports that those fac­tors could lead the drug to com­mand “some­where between” the $37 bil­lion we cur­rent­ly spend on Medicare Part B and the $90 bil­lion we cur­rent­ly spend on Medicare Part D. This lev­el of poten­tial new spend­ing, par­tic­u­lar­ly for just one prod­uct with lim­it­ed evi­dence of clin­i­cal effi­ca­cy thus far, tests the program’s resiliency.

… Medicare cov­er­age is lim­it­ed to items and ser­vices that are con­sid­ered “rea­son­able and nec­es­sary” for the diag­no­sis or treat­ment of an ill­ness or injury, fit with­in the scope of a ben­e­fit cat­e­go­ry, and are not oth­er­wise specif­i­cal­ly exclud­ed from cov­er­age. The Cen­ters for Medicare and Med­ic­aid Ser­vices (CMS) … may also need to make deci­sions about cov­er­age for poten­tial ancil­lary ser­vices like amy­loid PET scans. CMS might address these issues under its cur­rent author­i­ties through the issuance of a nation­al cov­er­age deter­mi­na­tion, which could autho­rize cov­er­age with­out restric­tion, lim­it cov­er­age, or delay full cov­er­age pend­ing col­lec­tion of more evi­dence. It might also be pru­dent for Con­gress to make pol­i­cy changes to enable Medicare to move towards val­ue-based pay­ment arrange­ments, which direct­ly con­nect pre­scrip­tion drug pric­ing to clin­i­cal effectiveness.

News in Context:

  • Can the con­tro­ver­sial FDA approval of Aduhelm back­fire and delay the dis­cov­ery of actu­al Alzheimer’s treat­ments? (Yes, it can)
  • US Sen­a­tor Joe Manchin calls for a new FDA Com­mis­sion­er to replace cur­rent (act­ing) one who “has repeat­ed­ly ignored pub­lic health con­cerns and shown a dere­lic­tion of duty” over opi­oids and aducanumab
  • First, do no harm? Six rea­sons to approach anti-amy­loid drug Aduhelm cau­tious­ly, if at all
  • Grow­ing back­lash against the FDA approval of unproven Alzheimer’s treat­ment Aduhelm, by Biogen

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: Aduhelm, Alzheimer's drug, amyloid PET scans, Biogen, Centers for Medicare and Medicaid Services, clinical efficacy, Medicare, Point32Health

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 35,342 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.